Every piece MicroCap Desk has published on Kazia Therapeutics, newest first. Independent editorial — we take no compensation from the companies we cover.
Kazia expanded its paxalisib breast-cancer trial and holds ~$46M, enough to fund operations into 2029.
Why a 50-year treatment plateau in glioblastoma is finally showing cracks.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.